Kirby Griffis faced a rough playing field as counsel for Novartis Corp. in serial litigation over a cancer-fighting drug alleged to cause the death of bone tissue in the jaw. Novartis had already lost two cases in Florida, and he was set to go to trial before a judge whose rulings suggested she thought this third case would go the same way.
He faced an undeniably sympathetic plaintiff — a 67-year-old woman in a wheelchair who beat late-stage breast cancer that had metastasized to her bones. Novartis’ Zometa saved her life, only to cause osteonecrosis — bone death, which leaves sufferers in constant pain and sometimes facially disfigured. While Griffis had terrific scientists as his expert witnesses, some were terrible public speakers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
